These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18223473

  • 1. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, Oellerich M, Armstrong VW.
    Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473
    [Abstract] [Full Text] [Related]

  • 2. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 3. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 27; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 4. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB, Karamperis N, Jørgensen KA.
    Transplant Proc; 2005 May 27; 37(4):1736-8. PubMed ID: 15919449
    [Abstract] [Full Text] [Related]

  • 6. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 20; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 8. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H, Okuyama K, Konno O, Jojima Y, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Uchiyama M, Ashizawa T, Matsuno N, Nagao T, Hirano T, Oka K.
    Transplant Proc; 2005 May 20; 37(4):1745-7. PubMed ID: 15919452
    [Abstract] [Full Text] [Related]

  • 9. Blood concentrations of everolimus are markedly increased by ketoconazole.
    Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL.
    J Clin Pharmacol; 2005 May 20; 45(5):514-8. PubMed ID: 15831774
    [Abstract] [Full Text] [Related]

  • 10. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 May 20; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun 20; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 12. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M, Wasler A, Prenner G, Tripolt M, Schwarz M, Tscheliessnigg KH.
    Transplant Proc; 2005 Dec 20; 37(10):4528-31. PubMed ID: 16387161
    [Abstract] [Full Text] [Related]

  • 13. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 20; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 20; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 15. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM, Snell GI, Valentine V, Aris R, Chan CK, Schmidli H, Pirron U.
    J Heart Lung Transplant; 2006 Apr 20; 25(4):440-6. PubMed ID: 16563975
    [Abstract] [Full Text] [Related]

  • 16. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.
    Koster RA, Dijkers EC, Uges DR.
    Ther Drug Monit; 2009 Feb 20; 31(1):116-25. PubMed ID: 19065123
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J.
    Hepatology; 2012 Nov 20; 56(5):1622-30. PubMed ID: 22576324
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
    Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, Baraldo M, Franceschi L, Furlanut M, Viale P.
    Ann Pharmacother; 2008 Nov 20; 42(11):1711-6. PubMed ID: 18812562
    [Abstract] [Full Text] [Related]

  • 19. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A.
    Transplant Proc; 2006 Dec 20; 38(10):3456-8. PubMed ID: 17175302
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 20; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.